Rafael Bejar, MD, PhD, Director of the MDS Center of Excellence at the Moores Cancer Center of the University of San Diego, explains what
mutations in individual
genes mean for the outlook with
myelodysplastic syndromes (
MDS). He also discusses the use of
biomarker testing to monitor and predict MDS disease course and the importance of
cytogenetic analysis to look for chromosomal abnormalities affecting MDS prognosis and treatment.
-
Share with family and friends:
Click here to take our SURVEY
Your feedback is important to us! We will use your feedback to develop future areas of content about MDS which will help other patients, caregivers and families.